CymaBay Therapeutics Presents Positive Phase 2 Data for Seladelpar in Patients with Primary Biliary Cholangitis at the International Liver Congress™ 2019

NEXT STORY
Helping to Add Esophageal Adenocarcinoma to the List of Preventable Cancers
PREV STORY
FameWave Announces Clinical Collaboration with Bristol Myers Squibb for the Planned Phase 1/2 Trial in Non-Small Cell Lung Cancer to Evaluate Immuno-Oncology Candidate CM-24 in Combination with Nivolumab (Opdivo®)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

[2020-2026] Global Adhesive Bandages Market Size, Share, Growth, Trends, Competitive Landscape, Revenue, Forecast Report Shared by Fortune Business Insights

author_avatar
NASDAQ Market News

“After the Smoke Clears” Brings Hope to Community on the Heels of Mental Health Awareness Month

author_avatar
NASDAQ Market News

Zai Lab Limited Announces Dosing of First Patient in Phase 3 Registration Trial of ZL-2306 (niraparib) for Treatment of Ovarian Cancer

SHANGHAI, China, Sept. 29, 2017 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based ...

author_avatar
NASDAQ Market News